Supplementary Data from Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore

• DOI: 10.1158/1078-0432.22473774.v1
• Publication Date: 2023-04-01T14:29:00Z
• Authors: Tessa G. Steenbru...; Maartje van Seijen; Liselore M. Janssen; Mette S. van Rams...; Erik van Werkhoven; Marie-Jeanne T.D....; Jelle Wesseling; Esther H. Lips; Gabe S. Sonke
• Keywords: Neoadjuvant Therapy

<p>Supplementary data to Steenbruggen TG, van Seijen M, Janssen LM, Ramshorst MS, Werkhoven E, Vrancken Peeters MJTDF, et al. Prognostic value of residual disease after neoadjuvant therapy in HER2-positive breast cancer evaluated by Residual Cancer Burden, Neoadjuvant Response Index & Neo-Bioscore. Table S1, S2, S3, S4, Text and legend Figure S1</p>